Business
Med BioGene reports promising pre-clinical results of its Diagnostic Lymphoma DNA Bioarray; biomarkers effective in diagnosing major lymphoma subtypes
Med BioGene reports promising pre-clinical results of its Diagnostic Lymphoma DNA Bioarray; biomarkers effective in diagnosing major lymphoma subtypes.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, Aug. 3 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased\nto announce the results of its pre-clinical studies involving its Diagnostic\nLymphoma Bioarray. The studies of fifty RNA samples derived from human\nlymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray successfully\ndifferentiated between genes in both the diseased and healthy control samples.\nMoreover, the results revealed a high dissimilarity between six lymphoma\nsubtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal\nZone and Small Lymphocytic) and the healthy control samples, indicating that\nthe bioarray is able to detect differential expression profiles. The samples\nused in the studies did not include the subtype T-Cell Lymphoma; however,\nprior studies suggest that the bioarray is able to distinguish this subtype\nfrom healthy control samples. Sample replicates were also highly similar to\none another, indicating a consistency in the bioarray.\n\"We are very pleased with these results and are enthusiastic about the\nprospects of our Diagnostic Lymphoma Bioarray as an effective tool for the\naccurate and rapid detection of lymphoma subtypes. We have been able to narrow\nour lymphoma biomarkers to approximately 100 genes, thus increasing the\neffectiveness of the product as a manageable diagnostic tool. Further studies,\nhowever, may result in the finding of additional biomarkers that will be\nincluded in our bioarray. These studies were performed on GE Healthcare's\nCodeLink System using custom bioarrays made exclusively for, and containing\ngenetic content developed by, Med BioGene. We are also in the process of\nconfirming our results on a second platform utilizing Applied BioSystem's 7500\nReal-Time PCR System\", noted Dr. T. Nathan Yoganathan, Chief Scientific\nOfficer of MBI.\n\"In addition to the use of our bioarray as a diagnostic tool, there is an\nincreasing consensus in the medical community that effective biomarkers are\nneeded to unlock innovation in therapeutic development and treatment. With a\nrobust set of qualified lymphoma biomarkers, the safety of new therapeutics\ncould be increased, products could get to patients in less time and treatment\ndecisions could be more informed. Med BioGene is truly at the forefront of\npersonalized medicine\", stated Erinn Broshko, Chief Executive Officer...